

28 April 2026

Syntara Limited (ASX: SNT) – Continuation of trading halt

Syntara Limited (Company) refers to the trading halt requested by the Company on 27 April 2026 pending an announcement in relation to correspondence from the U.S. Food and Drug Administration (FDA).

In light of FDA correspondence confirming a positive review of the Company's proposed clinical development plan and phase 2b clinical trial protocol, the Company is now proposing to undertake a material capital raising.

As such, the Company requests a continuation of the trading halt in respect of its ordinary shares (ASX: SNT).

For the purposes of Listing Rule 17.1, the Company provides the following information:

- a) The continuation of the trading halt is requested pending the release of an announcement by the Company regarding the proposed capital raising.
- b) The Company requests that the trading halt remains in place until the earlier of commencement of trading on Wednesday, 29 April 2026 and the time at which the Company makes an announcement to the market in relation to the proposed capital raising.
- c) The Company confirms that it is not aware of any reason why the continuation of the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

The ASX has agreed that the current trading halt will continue as requested above.

Yours sincerely
Syntara Limited



Timothy Luscombe
Chief Financial Officer / Company Secretary

Authorised for release by the Board of Syntara Limited.

For personal use only